| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
3 companies
Arch Venture Partners X, LLC is a 10% Owner at PRME, with reported holdings spanning 3 companies. Recent filings cover 7 purchases and 0 sales. Those positions are worth an estimated $36.3M at current prices.
Our model assigns Arch Venture Partners X, LLC a below-average insider score of 38/100, based on 5 past trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -36.1%.
Arch Venture Partners X, LLC's largest disclosed position is in PRME as 10% Owner, worth about $20.6M. Net of sales, the recent Form 4 record there shows accumulation of 7,030,300 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2025 | NMRA Neumora Therapeutics, Inc. | 10% Owner | Buy | 1,915,700 | $2.61 | $4,999,977.00 | +46.4% | -24.2% | -85.9% | |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | 10% Owner | Buy | 3,030,300 | $3.30 | $9,999,990.00 | +94.7% | +7.7% | -27.7% | |
| Feb 15, 2024 | PRME Prime Medicine, Inc. | 10% Owner | Buy | 3,200,000 | $6.25 | $20,000,000.00 | New | -13.3% | -63.6% | |
| Sep 19, 2023 | NMRA Neumora Therapeutics, Inc. | 10% Owner | Buy | 1,500,000 | $17.00 | $25,500,000.00 | +70.6% | +22.6% | +1.9% | |
| Sep 19, 2023 | NMRA Neumora Therapeutics, Inc. | 10% Owner | Buy | 1,500,000 | $17.00 | $25,500,000.00 | +70.6% | +22.6% | +1.9% | |
| Oct 24, 2022 | PRME Prime Medicine, Inc. | 10% Owner | Buy | 800,000 | $17.00 | $13,600,000.00 | +15.0% | +10.1% | -54.9% |